Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

The New Rules of the Road: An Update on CAR-T-Mediated Immune Reset for SLE

Sunday, October 26, 2025
1:00 PM – 2:00 PM Central Time

    Moderator(s)

  • Saira Sheikh, MD

    University of North Carolina at Chapel Hill
    Chapel Hill, NC, United States

    Disclosure(s): AstraZeneca: Advisor or Review Panel Member (Ongoing); Aurinia Pharmaceuticals: Advisor or Review Panel Member (Terminated, December 31, 2024); Biogen: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing)

  • SH

    Sarfaraz Hasni, MD, MSc

    National Institutes of Health
    Bethesda, Maryland, United States

    Disclosure information not submitted.

    • Session Coordinator(s)

  • SH

    Sarfaraz Hasni, MD, MSc

    National Institutes of Health
    Bethesda, Maryland, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

  • DeAnna Baker Frost, MD, PhD

    Assistant Professor
    Medical University of South Carolina
    Charleston, South Carolina, United States

    Disclosure(s): Allogene: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing)

  • AA

    Anca Askanase, MD, MPH

    Director
    Columbia University Medical Center
    New York, New York, United States

    Disclosure(s): Alumis: Advisor or Review Panel Member (Ongoing); Amgen: Advisor or Review Panel Member (Terminated, August 15, 2024); AstraZeneca: Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Cabaletta: Grant/Research Support (Ongoing); Genentech: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Advisor or Review Panel Member (Ongoing); NKARTA: Grant/Research Support (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Sanofi: Grant/Research Support (Ongoing); UCB: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing)

This session will familiarize the audience with the basic biology of CAR-T-mediated B cell immune reset and any new developments over the year. Clinicians will be updated on the different types of CAR-T therapy, including autologous, allogeneic, and the different B cell target antigens that may be utilized. There will also be a review of the available interim results of ongoing clinical studies of CAR-T therapy in systemic autoimmune disease, including SLE, scleroderma, myositis, ANCA-associated vasculitis, and perhaps others.

Learning Objectives:

  • Identify the basic biology of CAR-T-mediated B cell immune reset and review new developments in the field over the past year
  • Review the different types of CAR-T therapy under clinical investigation to achieve B cell immune reset, including autologous and allogeneic cells, and the different B cell antigens that may be targeted by the CAR-T therapy
  • Summarize available interim results of ongoing clinical studies of CAR-T therapy in systemic autoimmune disease, including SLE, scleroderma, myositis, ANCA-associated vasculitis, and others

Presentations:

  • 1:00 PM – 1:30 PM Central Time
    New Rules of the Road: Did Anybody Bring a Map?

    Speaker: Joan Merrill, MD – Oklahoma Medical Research Foundation

  • 1:30 PM – 2:00 PM Central Time
    TBD

    Speaker: Maximilian Konig, MD – The Johns Hopkins University School of Medicine